JSPR JSPR
Company Profile ↓Company Overview
JSPR (JSPR) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -77.78% |
| 6 Months: | -54.17% |
| 3 Months: | -31.69% |
| 1 Month: | +36.91% |
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)51.87 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 78.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -228.67K | -327.56K | -6.01M | -6.25M | -8.42M | -10.08M | -12.78M | -11.96M | -12.71M | -13.95M | -17.83M | -19.36M | -15.07M | -15.99M | -19.89M | -21.80M | -27.08M | -19.17M | -10.95M |
| Net Income | 1.43M | -3.43M | -201.19K | -9.75M | -8.41M | -3.41M | -2.21M | -10.40M | -11.86M | -14.26M | -16.08M | -17.54M | -13.73M | -14.58M | -18.64M | -21.24M | -26.72M | -18.74M | -1.17M |
| Diluted EPS | - | - | - | - | - | -0.69 | -0.06 | -0.29 | -0.32 | -1.62 | -1.47 | -1.60 | -1.03 | -0.97 | -1.24 | -1.41 | -1.74 | -1.13 | -0.04 |
| R&D Expense | - | - | 4.52M | 4.42M | 5.16M | 7.19M | 8.19M | 8.13M | 9.02M | 9.80M | 13.30M | 14.85M | 10.30M | 11.30M | 14.46M | 16.16M | 21.20M | 14.39M | 5.81M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -20.68M | -36.83M | -51.20M | -68.86M | -76.24M | -83.88M |
| Net Income | -31.67M | -30.64M | -37.69M | -64.47M | -71.27M | -75.80M |
| Diluted EPS | - | -2.69 | -10.33 | -6.18 | -4.89 | -3.95 |
| R&D Expense | 15.88M | 25.42M | 34.63M | 51.78M | 55.82M | 63.10M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | 101.69M | 23.36M | 93.65M | 48.36M | 94.89M | 79.90M | 35.78M |
| Total Equity | -4.73M | -35.13M | 69.52M | 35.99M | 78.44M | 61.67M | 4.15M |
| Cash & Equivalents | 1.21M | 19.84M | 84.70M | 38.25M | 86.89M | 71.64M | 28.69M |
| Total Liabilities | 3.61M | 14.65M | 24.14M | 12.37M | 16.45M | 18.23M | 31.63M |
| Current Liabilities | 111.36K | 4.01M | 8.02M | 7.07M | 12.37M | 15.24M | 13.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.27M | -33.68M | -45.86M | -52.07M | -62.60M | -77.16M |
| Investing Cash Flow | 198.34K | -2.43M | -576.00K | -267.00K | -532.00K | 5.00K |
| Financing Cash Flow | 11.29M | 100.97M | 55.00K | 100.97M | 47.88M | 34.21M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 90.1% | -44.1% | -104.7% | -82.2% | -115.6% | -1,826.1% |
| ROCE % | -106.9% | -43.0% | -124.0% | -83.4% | -117.9% | -371.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for JSPR
Jasper Therapeutics (JSPR) grants director option for 7,500 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPekdNeXRUUVZJczJTOS1aWC1Vdjg5SENlc1Y2OXg1aUlzX0xIcllNTWxncFB1b0dEOHA5YWVYSHd0blZtOHd4VmdXeVRNdFItVGNiUDFEZlQwb0toUVpLQ05yMVRzb1dBdUhfa3FLaFRQbkM4ejdXV0NCUU1VS0RMd2tWTHhvLXR6c05BZ1…
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNNDdwUjdOeTJJcG1MQ2Nlc0w1V3oyRFRQT3JCRzZ6WjZMR2lRZnpkNFFqVlB4ZkFFX0VzdWJXM3B1ZVptWE9UVndYLWQ0NkxQQW4yWC0xXzljTXNrMW04WlMzcldEWUluZUpMSlVlbFotMzJ2b2Y1TE1Td1VHU19fd0llZGh5d2E0eWdoMG…
Jasper Therapeutics (JSPR) grants 7,500-share stock option to board director - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOV2RwS3VxUFY2UERUUDhBSEpmREpUZGZYRXZucVgyTXl2MUx5TUxlM1ZLMG5RaHZlVnR2VzRlX0NiaVkwN2NKOGZfWnBoeFAwanBuaUY2em04VWF6am9fMW1FUm9iWDcwZFhfZmNLWHFLOFhYdlZETTA3WllYUXNUN0EyMVpiSHBMNEpoNH…
Jasper Therapeutics Company Profile & Introduction - Moomoo
<a href="https://news.google.com/rss/articles/CBMitwJBVV95cUxNNVR6QWYzZENmTjhMcWhLWUlzSUhhMHFDT1NKY0dYM3k0S25na0pVOEJHLTlKX2RhS1VmVTVWRDhOeVA4aW5GMWh4bkVVdV9UWGVxRjVJbEtGMW1ZN2FIWWVHczFoaTJiVFNJbGdPakdXRGxpRGVGcnQyTlFUbjhpR0VHUjB1ZmpYdXlteF…
JSPR|Jasper Therapeutics Inc|Price:0.630|Chg%:+0.009 - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE1BQlZhU01kT0d5VndQTnRjNmFTUlQyWUpXWlFvZXJRenRVOWFTbS1uX1ZkSUx5QnNBcS16TTNzVng2RngzZFYzcnRVbWJOVmItLU9YVXFyUVIxdw?oc=5" target="_blank">JSPR|Jasper Therapeutics Inc|Price:0.630|Chg%…
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7 - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPVWkybk56d1cyQm5xdF95eWc4QTcxSmdqLVh4YXZwLUxXNzg2UDVCbDdQQWU3UlNfakhJZ1hJb1Ywb2JkTDhReXVkQ0tWeFc0XzlDdWo5SUdqd2V3OHVoZlVma2s2YUE1RnI0akZEdmsxNEZMdTJaZkl6OEJNcE1UWkYzaU5kelVBcmRiNm…
JSPR — Frequently Asked Questions
What is the current share price of JSPR?
As of 2026-08-05 17:25 PDT, JSPR trades at $0.66 on NASDAQ/NYSE. Its 52-week range is $0.34 to $3.11.
What is the P/E ratio of JSPR?
JSPR trades at a trailing price-to-earnings (P/E) ratio of -0.17.
Is JSPR a good stock to buy?
This page provides a data-driven analysis of JSPR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.